Literature DB >> 25712759

Animal Farm: Considerations in Animal Gastrointestinal Physiology and Relevance to Drug Delivery in Humans.

Grace B Hatton1, Vipul Yadav1, Abdul W Basit1, Hamid A Merchant2.   

Abstract

"All animals are equal, but some are more equal than others" was the illustrious quote derived from British writer George Orwell's famed work, Animal Farm. Extending beyond the remit of political allegory, however, this statement would appear to hold true for the selection of appropriate animal models to simulate human physiology in preclinical studies. There remain definite gaps in our current knowledge with respect to animal physiology, notably those of intra- and inter-species differences in gastrointestinal (GI) function, which may affect oral drug delivery and absorption. Factors such as cost and availability have often influenced the choice of animal species without clear justification for their similarity to humans, and lack of standardization in techniques employed in past studies using various animals may also have contributed to the generation of contradictory results. As it stands, attempts to identify a single animal species as appropriately representative of human physiology and which may able to adequately simulate human in vivo conditions are limited. In this review, we have compiled and critically reviewed data from numerous studies of GI anatomy and physiology of various animal species commonly used in drug delivery modeling, commenting on the appropriateness of these animals for in vivo comparison and extrapolation to humans.
© 2015 Wiley Periodicals, Inc. and the American Pharmacists Association.

Entities:  

Keywords:  absorption; animal models in drug delivery; bioavailability; in vitro/in vivo correlations; oral drug delivery; pharmacokinetic/pharmacodynamic models; preclinical pharmacokinetics; preclinical species

Mesh:

Year:  2015        PMID: 25712759     DOI: 10.1002/jps.24365

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  35 in total

1.  The functional role of protease-activated receptors on contractile responses by activation of Ca2+ sensitization pathways in simian colonic muscles.

Authors:  Tae Sik Sung; Hongli Lu; Juno Sung; Jong Hoon Yeom; Brian A Perrino; Sang Don Koh
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2018-09-27       Impact factor: 4.052

2.  Nanoparticulate Drug Delivery Systems Targeting Inflammation for Treatment of Inflammatory Bowel Disease.

Authors:  Sufeng Zhang; Robert Langer; Giovanni Traverso
Journal:  Nano Today       Date:  2017-10-09       Impact factor: 20.722

Review 3.  "Good Fences Make Good Neighbors": How does the Human Gut Microchip Unravel Mechanism of Intestinal Inflammation?

Authors:  Woojung Shin; Landon A Hackley; Hyun Jung Kim
Journal:  Gut Microbes       Date:  2019-06-14

Review 4.  Comparison of Canine and Human Physiological Factors: Understanding Interspecies Differences that Impact Drug Pharmacokinetics.

Authors:  Marilyn N Martinez; Jonathan P Mochel; Sibylle Neuhoff; Devendra Pade
Journal:  AAPS J       Date:  2021-04-27       Impact factor: 4.009

5.  Gastroretentive Sustained-Release Tablets Combined with a Solid Self-Micro-Emulsifying Drug Delivery System Adsorbed onto Fujicalin®.

Authors:  Yoshihiro Omachi
Journal:  AAPS PharmSciTech       Date:  2022-06-08       Impact factor: 3.246

Review 6.  A Critical Overview of the Biological Effects of Excipients (Part II): Scientific Considerations and Tools for Oral Product Development.

Authors:  Marilyn N Martinez; Fang Wu; Balint Sinko; David J Brayden; Michael Grass; Filippos Kesisoglou; Aaron Stewart; Kiyohiko Sugano
Journal:  AAPS J       Date:  2022-05-02       Impact factor: 4.009

Review 7.  Foundations of gastrointestinal-based drug delivery and future developments.

Authors:  Jacqueline N Chu; Giovanni Traverso
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2021-11-16       Impact factor: 46.802

8.  Nanoparticles that do not compete with endogenous ligands - Molecular characterization in vitro, acute safety in canine, and interspecies pharmacokinetics modeling to humans.

Authors:  Dianxiong Zou; Meenakshi Arora; Raghu Ganugula; Mokshada Kumar; Erin M Scott; Dhaval Shah; M N V Ravi Kumar
Journal:  J Control Release       Date:  2021-02-16       Impact factor: 9.776

9.  Diet, obesity, and the gut microbiome as determinants modulating metabolic outcomes in a non-human primate model.

Authors:  Tiffany M Newman; Carol A Shively; Thomas C Register; Susan E Appt; Hariom Yadav; Rita R Colwell; Brian Fanelli; Manoj Dadlani; Karlis Graubics; Uyen Thao Nguyen; Sivapriya Ramamoorthy; Beth Uberseder; Kenysha Y J Clear; Adam S Wilson; Kimberly D Reeves; Mark C Chappell; Janet A Tooze; Katherine L Cook
Journal:  Microbiome       Date:  2021-05-05       Impact factor: 14.650

10.  Characterization of an engineered live bacterial therapeutic for the treatment of phenylketonuria in a human gut-on-a-chip.

Authors:  M Tyler Nelson; Mark R Charbonneau; Heidi G Coia; Mary J Castillo; Corey Holt; Eric S Greenwood; Peter J Robinson; Elaine A Merrill; David Lubkowicz; Camilla A Mauzy
Journal:  Nat Commun       Date:  2021-05-14       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.